FDA asks company to remove opioid drug from market
The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.
Related News Articles
Headline
Erica Taylor, M.D., orthopedic surgeon and vice president of health equity at Duke Health, shares how the organization’s frontline liaison network is helping…
Chairperson's File
At every hour of every day, people across the U.S. count on their local hospital. For many people, emergencies happen without warning — a heart attack,…
AHA Cyber Intel
While we may feel inundated with alarming news about escalating cyber threats against healthcare organizations, there is also some good news. Let’s explore how…
Headline
A multistate cyclospora outbreak linked to iceberg lettuce has been declared over, the Centers for Disease Control and Prevention and Food and Drug…
Perspective
Twenty-five years ago, our nation experienced one of the darkest days in its history. The terrorist attacks of Sept. 11, 2001, took thousands of innocent lives…
Headline
The Federal Office of Rural Health Policy’s Rural Health Redesign Center will host a webinar on Sept. 24 at 2 p.m. ET, where hospital CEOs will discuss the…